|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abou-Alfa GK, Lau G, Kudo M, Chan SL,
Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni
EN, et al: Tremelimumab plus durvalumab in unresected
hepatocellular carcinoma. N Eng J Med Evid.
1:EVIDoa21000702022.
|
|
5
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLB strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikenaga N, Chijiwa K, Otani K, Ohuchida J,
Uchiyama S and Kondo K: Clinicopathologic characteristics of
hepatocellular carcinoma with bile duct invasion. J Gastrointest
Surg. 13:492–497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu JY, Sun JX, Wu JY, Huang XX, Bai YN,
Wei YG, Zhang ZB, Zhou JY, Cheng SQ and Yan ML: Impact of bile duct
tumor thrombus on the long-term surgical outcomes of hepatocellular
carcinoma patients: A propensity score matching analysis. Ann Surg
Oncol. 29:949–958. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hiraoka A, Michitaka K, Kumada T, Izumi N,
Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M,
et al: Validation and potential of albumin-bilirubin grade and
prognostication in a nationwide survey of 46,681 hepatocellular
carcinoma patients in Japan: The need for a more detailed
evaluation of hepatic function. Liver Cancer. 6:325–36. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eisenheauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1.). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudo M, Aoki T, Ueshima K, Tsuchiya K,
Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, et al:
Achievement of complete response and drug-free status by
atezolizumab plus bevacizumab combined with or without curative
conversion in patients with transarterial
chemoembolization-unsuitable, intermediate-stage hepatocellular
carcinoma: A multicenter proof-of-concept study. Liver Cancer.
12:321–338. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kelley RK, Sangro B, Harris W, Ikeda M,
Okusaka T, Kang YK, Qin S, Tai DWM, Lim HY, Yau T, et al: Safety,
efficacy, and pharmacodynamics of tremelimumab plus durvalumab for
patients with unresectable hepatocellular carcinoma: Randomized
expansion of a phase I/II study. J Clin Oncol. 39:2991–3001. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kudo M: Current therapeutic strategies for
hepatocellular carcinoma in Japan. Liver Cancer. 12:497–509. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kudo M: Scientific rationale for combined
immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in
advanced hepatocellular carcinoma. Cancers. 12:10892020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho YK and Jung CH: Immune-checkpoint
inhibitors-induced type 1 diabetes mellitus: From its molecular
mechanisms to clinical practice. Diabetes Metab J. 47:757–766.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Johnson ML, Cho BC, Luft A,
Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G,
Hussein M, Lim FL, et al: Durvalumab with or without tremelimumab
in combination with chemotherapy as first-line therapy for
metastatic non-small-cell lung cancer: The phase III POSEIDON
study. J Clin Oncol. 41:1213–1227. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yeh TS, Wang F, Chen TC, Yeh CN, Yu MC,
Jan YY and Chen MF: Expression profile of microRNA-200 family in
hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg.
259:346–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu LB, Qin YF, Su L, Huang C, Xu Q, Zhang
R, Shi XD, Sun R, Chen J, Song Z, et al: Cathepsin-facilitated
invasion of BMI1-high hepatocellular carcinoma cells drives bile
duct tumor thrombi formation. Nat Commun. 14:70332023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanaka T, Kuzuya T, Ishigami M, Ito T,
Ishizu Y, Honda T, Ishikawa T and Fujishiro M: Efficacy and safety
of sorafenib in unresectable hepatocellular carcinoma with bile
duct invasion. Oncology. 98:621–629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sho T, Suda G, Ogawa K, Shigesawa T,
Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka
M, et al: Lenvatinib in patients with unresectable hepatocellular
carcinoma who do not meet the REFLECT trial eligibility criteria.
Hepatol Res. 50:966–977. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Komatsu S, Fujishima Y, Kido M, Kuramitsu
K, Goto T, Yanagimoto H, Toyama H and Fukumoto T: Significant
response to atezolizumab plus bevacizumab treatment in unresectable
hepatocellular carcinoma with portal vein tumor thrombus: A case
report. BMC Gastroenterol. 21:4702021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kurisaki K, Soyama A, Hara T, Matsushima
H, Imamura H, Tanaka T, Adachi T, Ito S, Kanetaka K, Hidaka M, et
al: Pathologic complete response after chemotherapy with
atezolizumab plus bevacizumab for hepatocellular carcinoma with
tumor thrombus in the main portal trunk. Dig Surg. 40:84–89. 2023.
View Article : Google Scholar : PubMed/NCBI
|
